Table 2.

Therapeutic results of apatinib in the patients.

	Patient 1	Patient 2	Patient 3
EGFR-TKI co-therapy	AZD3759	Gefitinib	AZD9291
Duration of apatinib treatment, days	42	46	22
Withdrawal reason	PD	PD	Hemoptysis
PFS, months	1.4	1.5	–
Adverse events
Hypertension	Grade 1	Grade 3	–
Hand-foot syndrome	Grade 3	–	–
Hemorrhage	–	–	Grade 5
Diarrhea	Grade 1	–	–
Cardiac toxicity	–	–	–
Bone marrow suppression	–	–	–

Abbreviations: PD, progression disease; PFS, progression-free survival; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.